Humalog (Insulin Lispro) Injection shortage
Not a nationwide shortage — Eli Lilly and has told the FDA it is discontinuing its insulin lispro injections. The FDA lists this under “To be discontinued” as of Oct 5, 2026: a company stopping its own product. 2 other companies list the same medicine with the FDA and have not reported a shortage.
Eli Lilly is permanently discontinuing its insulin lispro 100 units/mL Tempo Pen, with distribution expected to end June 2027. Other insulin lispro products — including Humalog KwikPen, Humalog Junior KwikPen, and Admelog — are still listed as available from other manufacturers.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this medicine? See the ‘What to do’ note from Dr. Brian Staiger, PharmD →Is Humalog still in shortage? — status as of Oct 5, 2026
Not as a nationwide shortage. Eli Lilly and is stopping its own product; 2 other companies still list the same medicine.
The charts count only the companies that reported this shortage to the FDA; companies that haven’t reported a problem are in the green card, and the Supply-Risk rating counts them too.
Shortage timeline
-
Sep 1, 2026Currently in shortage2 of 2 products affected.
-
Sep 1, 2026More presentations reported1 more product added to the shortage.
-
Oct 24, 2025First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which Humalog products are affected — by company
Company: Eli Lilly and Co. 📞 800-545-5979 2 NDCS click to expand
| Status | NDC / product | Strength / size | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Insulin Lispro Injection, 100 [IU]/1 mL | 100 [IU]/1 mL | — | A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance. | — |
| To Be Discontinued | Humalog Injection | U-100 Tempo Pen | — | A business decision was made to discontinue manufacture of the drug. | — |
These rows are company reports to the FDA for Insulin Lispro Injection — they do not cover every company that lists this medicine. A company appears here only if it told the FDA it has a supply problem, so other companies may still have stock. That’s the basis for the Where else can I get Humalog or its generic? options further down this page.
Why is Eli Lilly and discontinuing Humalog?
Eli Lilly has made a business decision to permanently stop making two specific insulin lispro products: the Insulin Lispro Junior KwikPen (100 units/mL) and the Humalog U-100 Tempo Pen. No specific public reason beyond it being a business decision was shared with the FDA. For the Junior KwikPen, distribution is expected to end in June 2027. The Humalog U-100 Tempo Pen does not have a projected end-distribution date listed in the report.
It's worth knowing that this report covers only these two specific Lilly products — the Junior KwikPen and the Tempo Pen — not every form of insulin lispro that Lilly makes. If you have questions directly about these changes, Lilly's answers center can be reached at 1-800-545-5979, Monday through Friday, 9 AM to 8 PM.
Based on the company-reported reason(s) and notes on file with the FDA for Insulin Lispro Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as companies report changes.
What should I do if I take Humalog?
Insulin Lispro Injection is currently on the FDA shortage list, and I want to walk you through what this means for you.
This report covers two products from Eli Lilly: the Junior KwikPen (100 iU/1 mL) and the Humalog U-100 Tempo Pen. Both are listed with no available source right now, and neither strength on this record currently shows supply. Because the reason given is a business decision to discontinue these products — with distribution of the 100 iU/1 mL projected to end June 2027 — this supply problem may be permanent for these specific items. That makes a conversation with your prescriber the right next step, though there is time to plan.
Here is what I suggest, in order:
- Do not stop, skip, or change your insulin on your own — insulin is essential and steady dosing matters.
- Ask your pharmacy to check wholesalers, since local stock can differ from national reports.
- The same medicine (insulin lispro) is still made by others — for example Humalog KwikPen, Humalog Junior KwikPen, and Admelog. Your pharmacy may be able to source one of these, though it may not be in local stock.
- Ask your prescriber or pharmacist which option fits you best.
The manufacturer's number (Eli Lilly, 800-545-5979) is listed on this page for reference. This is general, national information and may not match your pharmacy's actual stock.
- Ask your pharmacy to check other companies’ versions, other strengths / sizes, package sizes, and nearby stores — the options below are a starting point.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Humalog or its generic?
FDA shortages are company-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every company that lists insulin lispro injections is necessarily short. Below are the other listings in the current FDA NDC Directory that are not reported in shortage: the same medicine from companies that haven’t reported a problem (the reporting company is excluded), and other dosage forms. These are generic versions of Humalog — a switch from the brand goes through your pharmacist or prescriber. Some listings are repackagers, which relabel another company’s product. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine from other companies (not reporting a shortage)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from companies that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Company | NDC |
|---|---|---|---|---|
| Admelog | INSULIN LISPRO 100 U/mL | Injection, Solution · Subcutaneous | Sanofi-Aventis U.S. LLC | 00024-5925-00 |
| Admelog | INSULIN LISPRO 100 U/mL | Injection, Solution · Subcutaneous | REMEDYREPACK INC. | 70518-4275-00 |
Therapeutic equivalents & pricing 7 productsclick to expand
Orange Book–rated equivalents of the affected strengths / sizes, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Humalog Mix75/25 100 [iU]/mL | Eli | 1 vial | $8.153 | — | Availability likely |
| Humalog Tempo Pen 100 [iU]/mL | Eli | 5 syringes | $10.127 | — | Availability likely |
| Humalog Mix50/50 KwikPen 100 [iU]/mL | Eli | 5 syringes | $10.141 | — | Availability likely |
| Humalog Junior KwikPen 100 [iU]/mL | Eli | 5 syringes | $10.158 | — | Availability likely |
| Humalog Mix75/25 KwikPen 100 [iU]/mL | Eli | 5 syringes | $10.167 | — | Availability likely |
| Insulin Lispro Junior KwikPen 100 [iU]/mL | Eli | 5 syringes | $10.199 | — | Availability likely |
| Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen 100 [iU]/mL | Eli | 5 syringes | $10.207 | — | Availability likely |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Humalog — that fall in the same broad treatment class (insulins) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Codes & classification for pharmacists and billers
Where does this data come from?
Other endocrinology/metabolism shortages
Humalog shortage FAQs
Is Humalog still in shortage?
Which strengths / sizes of Humalog are affected?
Which Humalog products are affected?
When will Humalog be available again?
Can I still get Humalog or its generic somewhere?
Is the brand or the generic affected?
What should I do if I take Humalog?
Still have a question about the Humalog shortage?
Ask a pharmacist about this shortage →View Insulin Lispro Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (companies listing the same ingredient & form — the "other companies" the rating counts); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.